Ventripoint Diagnostics Launches Targeted Congenital Heart Defect Marketing Program, Setting Stage for Multi-Segment Growth

Toronto, Ontario, August 15, 2025 – Ventripoint Diagnostics Ltd. ("**Ventripoint**" or the "**Corporation**", TSXV:VPT; OTC:VPTDF) a leader in AI-powered heart analysis solutions, today announced the launch of a targeted marketing program focused on the diagnosis and monitoring of congenital heart defects (CHD). The initiative is designed to solidify Ventripoint's leadership position in this high-need clinical area, while laying the foundation for expansion into other rapidly growing segments including cardio-oncology, pulmonary hypertension, heart failure, and valvular heart disease.

The new program will spotlight the Company's flagship VMS+™ system, which delivers MRI-comparable volumetric and functional cardiac measurements using standard echocardiography. This capability eliminates many of the patient and workflow barriers associated with cardiac MRI - particularly critical for CHD patients, who often require frequent monitoring from infancy through adulthood.

"CHD patients face a lifetime of imaging, yet many cannot access MRI due to cost, availability, or clinical limitations," said Hugh MacNaught, President and CEO of Ventripoint Diagnostics. "Our VMS+ technology solves that challenge by enabling fast, accurate, and comfortable assessments using widely available ultrasound equipment. By leading in CHD, we are also building the clinical credibility and installed base needed to accelerate adoption in other high-value segments."

The CHD-focused marketing program will include:

- Collaboration with Industry Partners – Continuing to actively work with partners such as ASCEND Cardiovascular to cross-market and promote AI enhanced echocardiography solutions.

- Specialized Clinical Education – Building on our relationships with pediatric and adult congenital cardiology centers to demonstrate workflow integration and patient benefits.

- Patient Advocacy Engagement – Continuing the collaboration with the Ollie Hinkel Heart Foundation and developing relationships with other CHD advocacy organizations to increase awareness of advanced, accessible imaging options.

- Key Opinion Leader (KOL) Partnerships – Working with our clinical advisors to publish CHD case studies and peer-reviewed data that reinforce VMS+ as the standard of care for functional cardiac assessment without MRI.

By establishing a leadership position in CHD, Ventripoint expects to accelerate uptake in additional clinical areas where fast, non-invasive, and accurate cardiac volumetric analysis is in demand - such as monitoring heart damage in cancer patients (cardio-oncology), tracking right heart changes in pulmonary hypertension, assessing cardiac performance in heart failure, and assessing suitability of patients for valve repair and replacement procedures in addition to monitoring outcomes.

“Each of these markets represents a significant growth opportunity, but CHD offers a unique platform for proving our value proposition in the most challenging and underserved patient population,” added Hugh MacNaught. “From there, our addressable market expands exponentially.”

Ventripoint will provide updates on program milestones and commercial progress in its upcoming quarterly communications.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Hugh MacNaught
hmacnaught@ventripoint.com
604-671-4201

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the

Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct.

Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management's discussion and analysis that is available on the Corporation's profile on SEDAR+ at www.sedarplus.ca. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.